HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Are Wrinkle Treatments With AHAs, BHAs OTCs? FDA Issues Call For Data

This article was originally published in The Rose Sheet

Executive Summary

FDA is requesting information on the possible physiological effects of alpha hydroxy and beta hydroxy acids in wrinkle removers to help evaluate their regulatory status, according to a Dec. 31 Federal Register notice

Related Content

Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says
CFSAN Cosmetics Oversight Aided By NTP, CDER Collaboration
Cosmetic Claim Review Should Not Make CFSAN Priority Cut – CTFA
FDA Has “Ample Regulatory Authority” To Oversee Cosmetics – McNeil
Carcinogens In Cosmetics Need Oversight, Environmental Group Claims
AHA, BHA Products Are Cosmetics Based On Legal Precedent – CTFA
CFSAN/CDRH Study Examines Potential Skin Damage From Hydroxy Acids
FDA Draws The Line On Wrinkle Reduction Claims In Warning Letter
California Biomonitoring Bill Seeks Fees From Companies Using Triclosan
“Sunburn Alert” Labeling For AHA Products Recommended By FDA



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts